Krystal Biotech ( NASDAQ:KRYS – Get Free Report ) last released its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The company had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. Equities analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.